New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
06:00 EDTAGN, WFMStocks with implied volatility below IV index mean; AGN WFM
Stocks with implied volatility below IV index mean; Allergan (AGN) 25, Whole Foods (WFM) 23 according to iVolatility.
News For AGN;WFM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
11:11 EDTWFMWhiteWave hits 52-week high following upbeat analyst notes
Subscribe for More Information
March 23, 2015
16:14 EDTAGNPershing Square liquidates stake in Allergan
Subscribe for More Information
09:37 EDTWFMActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
09:03 EDTAGNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 19, 2015
07:35 EDTWFMKroger price target raised to $90 from $80 at Deutsche Bank
Subscribe for More Information
March 18, 2015
09:57 EDTWFMWhole Foods Markets calls active on renewed takeover chatter
Whole Foods Markets March 53, 54 and April 55 calls are active on 8K contracts (1K puts) on renewed takeover chatter. March call option implied volatility is at 38, April is at 25, May is at 30; compared to its 26-week average of 27 according to Track Data. Active call volume suggests traders taking positions for larger near term price movement.
09:43 EDTWFMRumor: Whole Foods active on renewed takeover chatter
Subscribe for More Information
March 17, 2015
09:13 EDTAGNActavis says Allergan CEO not joining combined company board
Subscribe for More Information
08:58 EDTAGNActavis sees double digit accretion to adjusted EPS within first 12 months
08:58 EDTAGNActavis says will 'immediately begin implementing' integration plans
Subscribe for More Information
08:57 EDTAGNActavis completes acquisition of Allergan
Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.
08:56 EDTAGNActavis completes Allergan acquisition valued at $70.5B
Subscribe for More Information
March 16, 2015
18:38 EDTAGNAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
Subscribe for More Information
17:19 EDTAGNAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
10:22 EDTAGNEuropean Commission clears Actavis' pending acquisition of Allergan
Subscribe for More Information
10:14 EDTAGNOptions with decreasing implied volatility
Options with decreasing implied volatility: EXPR ULTA SGMS QIHU BKS PAY URBN AGN AGNC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use